lunes, 16 de noviembre de 2026
FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics It’s a regulatory setback for Summit, though one that was not entirely unforeseen
https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/
By Adam FeuersteinNov. 15, 2026
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.
Suscribirse a:
Enviar comentarios (Atom)


No hay comentarios:
Publicar un comentario